Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · PALVELLA THERAPEUTICS, INC. (PVLA)

Palvella Therapeutics Q3 net loss widens to $24.6 million; FDA accepts NDA for QTORIN

Mixed Impact 3 of 5 earnings Written later

Palvella Therapeutics reported a third-quarter 2026 net loss of $24.6 million, or $1.70 per share, up from $11.3 million, or $1.03 per share, a year earlier, as research and development and general and administrative expenses rose sharply. The company said the FDA accepted its NDA for QTORIN rapamycin for microcystic lymphatic malformations with Priority Review and a February 28, 2027 PDUFA target action date, and it ended the quarter with $236.7 million in cash, cash equivalents and short-term investments.

Key points

  • Net loss of $24.6 million ($1.70 per share) for the quarter ended September 30, 2026, versus $11.3 million ($1.03 per share) a year earlier
  • R&D expenses rose to $10.8 million from $6.5 million; G&A expenses rose to $11.9 million from $3.6 million
  • FDA accepted the NDA for QTORIN rapamycin with Priority Review; PDUFA target action date is February 28, 2027
  • Cash, cash equivalents and short-term investments were $236.7 million as of September 30, 2026

The filing

CompanyPALVELLA THERAPEUTICS, INC. (PVLA)
Form8-K, current report
Filed with the SECNov 5, 2026, 7:30 AM ET
Accession number0001193125-26-448594

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.